Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense.
Viscusi
W K
WK
Duke University, USA.
Rowland
S R
SR
Dorfman
H L
HL
Walsh
C J
CJ
D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000191:economics / Q000331:legislation & jurisprudence*; D004348:Drug Labeling / Q000331:legislation & jurisprudence* / Q000592:standards; D007885:Legislation, Pharmacy / Q000191:economics; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration; D026712:Value of Life